Dementia Matters

AAIC Special Series Part 5: Bringing together scientists, clinicians, and research participants from all over the world, AAIC 2022 showcases the work and experiences of people from unique backgrounds and perspectives and highlights the importance of diversity in Alzheimer’s disease research. Dr. Carl Hill joins the podcast to discuss why diversity is important in scientific research and how AAIC 2022 supports efforts to make Alzheimer’s disease research more equitable and inclusive. Guest: Carl Hill, PhD, MPH, chief diversity, equity and inclusion officer, Alzheimer’s Association Show Notes AAIC is the world’s largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Listen to our past episode of Dementia Matters with Dr. Carl Hill on our website, Spotify, Apple Podcasts, YouTube, or wherever you get your podcasts.  Learn more about Dr. Carl Hill on the Alzheimer’s Association website. Learn more about Henrietta Lac

AAIC Special Series Part 4: Research into delirium, a condition where older adults experience acute confusional states during hospitalizations, and its connections to dementia have led to  numerous advancements in hospital care and treatments. Dr. Sharon Inouye joins the podcast to discuss how our understanding of delirium has changed over the past 30 years and previews her upcoming AAIC plenary talk about the intersection of delirium and dementia. Guest: Sharon Inouye, PhD, director, Aging Brain Center, Hinda and Arthur Marcus Institute for Aging Research, professor, Harvard Medical School Show Notes AAIC is the world’s largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Inouye at her bio on the Marcus Institute for Aging Research website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter.

AAIC Special Series Part 3: Mild cognitive impairment (MCI) is an early stage of memory loss and cognitive impairment that can develop into dementia. While physicians have medications they can prescribe to manage the condition, many researchers and doctors are focusing on lifestyle interventions that could support a person’s cognition and address behavioral changes. Dr. Linda Lam joins the podcast to discuss her work studying mild cognitive impairment and preview her upcoming AAIC plenary talk on non-pharmacological treatments for MCI and dementia. Guest: Linda Lam, MBChB, MD, professor, Chinese University of Hong Kong Show Notes AAIC is the world’s largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Linda Lam on the Chinese University of Hong Kong website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Faceb

AAIC Special Series Part 2: Attending scientific conferences is usually a major commitment, often requiring attendees to travel, pay attendance fees, and take time out during the day to learn about groundbreaking research. Recent conferences like the Alzheimer’s Association International Conference (AAIC) are opening their doors virtually to make the events more accessible to research participants, care partners, and the general public. Sarah Walter joins the podcast as part of our special series previewing AAIC 2022 to discuss her article on how virtual scientific conferences impact research participant engagement and why it’s important for participants to hear about the research they’re involved in. Guest: Sarah Walter, MSc, program administrator, Alzheimer's Clinical Trials Consortium, Alzheimer's Therapeutic Research Institute, University of Southern California Show Notes AAIC is the world’s largest forum for the dementia research community. Register for the plenary events, which are free to the public wi

AAIC Special Series Part 1: To kick off our month-long special series previewing the 2022 Alzheimer’s Association International Conference, or AAIC, we’ve invited  Claire Sexton, senior director of the Alzheimer’s Association’s scientific programs, to join us to discuss the goals of AAIC, how the pandemic impacted the influential conference, and what she’s looking forward to at this year’s event. Guest: Claire Sexton, DPhil, senior director of scientific programs and outreach, Alzheimer’s Association Show Notes The AAIC is the world’s largest forum for the dementia research community. Register for the plenary events, which are free to the public with registration, at the AAIC website. Learn more about Dr. Claire Sexton on the Alzheimer’s Association website. Connect with us Find transcripts and more at our website. Email Dementia Matters at dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

A do-not-resuscitate, or DNR, order is used to indicate when a patient chooses to forgo resuscitation, however recent analysis shows that multiple studies have connected the presence of DNR orders to elevated death rates, poorer medical care, and negative health outcomes. Dr. Jonathan Baktari joins the podcast to discuss the findings from this analysis, how it can impact individuals with Alzheimer’s disease and dementia, and how these concerns can be addressed. Guest: Jonathan Baktari, MD, CEO, chief medical officer, e7 Health Show Notes Read about Dr. Baktari’s analysis, “DNR Orders Can Lead to Worse Care & Increase Death Rates,” on the e7 Health website. Learn more about Dr. Baktari at his bio on his website. Connect with us: Find transcripts and more at our website. Email Dementia Matters. Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

American literature professor and author Cindy Weinstein and behavioral neurologist Bruce Miller join the podcast to discuss their latest book, "Finding the Right Words: A Story of Literature, Grief, and the Brain", a dual-memoir that alternates between Weinstein’s memories of her father who experienced early-onset Alzheimer’s disease and Miller’s scientific responses. They discuss their writing process, developments in Alzheimer's disease research, and their experiences as care partners and care providers to those experiencing dementia. Guests: Cindy Weinstein, PhD, Eli and Edythe Broad Professor of English, California Institute of Technology and Bruce Miller, MD, director, University of California San Francisco Memory and Aging Center Episode Topics 5:36 What brought the two of you together to write Finding the Right Words? 7:40 Cindy, how long have you thought about writing this book about your father, and how long did it take you to write this book? 14:36 What did you want the reader to take away from thi

There are many conflicting studies on how alcohol consumption can impact a person’s health, with some studies suggesting light drinking can protect against coronary heart disease and others concluding that drinking can increase your risk for cancer. What does research say about alcohol and the brain? Dr. Remi Daviet joins the podcast to discuss his latest study that found that just one alcoholic drink a day was associated with brain shrinkage, and drinking more could increase that rate exponentially over time. Guest: Remi Daviet, PhD, assistant professor, Wisconsin School of Business Episode Topics 3:40 How do you suggest people balance all of the conflicting messages surrounding research on alcohol consumption? 7:30 Is there an interaction between alcohol consumption and getting older? 8:10 What did your results show in this study? 13:45 How are you defining alcohol consumption? What is a unit of alcohol defined as for beer, wine, and hard alcohol? Show Notes Read Dr. Daviet’s study, Associations between al

In honor of Women’s Health Month, Dr. Jessica Caldwell joins the podcast to discuss sex differences in aging and Alzheimer’s disease. She explains some of the ways women experience aging and Alzheimer’s disease differently than men and how she incorporates research findings into patient care.  Guest: Jessica Caldwell, PhD, director, Women’s Alzheimer’s Movement Prevention Center, Cleveland Clinic in Las Vegas, assistant professor, Case Western Reserve University Episode Topics 2:59 What are the sex differences in experiencing normal aging and in experiencing Alzheimer’s disease? 7:33 Why are women more affected by Alzheimer’s disease than men? 10:03 Are there other theories that have been speculated but aren’t true regarding the differences between men and women aging? 23:18 What type of prevention approaches do you discuss in your clinic? Show Notes The Women’s Alzheimer’s Movement Prevention Center at Cleveland Clinic in Las Vegas is the world’s first Alzheimer’s prevention center exclusively for women. Lea

A graduate student from the University of Wisconsin–Madison is pushing for the disaggregation of data in research to better understand how individuals from different ethnic subgroups are represented as research participants and as researchers. Kao Lee Yang began writing and discussing the topic after the Howard Hughes Medical Institute’s Gilliam Fellowship for Advanced Study rejected her application for not meeting their racial and ethnic underrepresentation criteria, despite often being the only Hmong American scientist in many research spaces. Yang joins the podcast to discuss her opinion piece for STAT News, the problems with using aggregated data, and how the push to study individual ethnic groups could improve Alzheimer’s disease research. Guest: Kao Lee Yang, MPA/PhD candidate in the Neuroscience and Public Policy Program and Bendlin Laboratory, University of Wisconsin–Madison Episode Topics 6:12 Why is combining all Asian people into one category detrimental? What is improved when this population is br

Dr. Cynthia Carlsson and Daniel A. King join the podcast to discuss some of the unique ways that Alzheimer’s disease affects veterans and Native Americans. Their work at the Wisconsin Alzheimer’s Disease Research Center allows them to connect with people who are at higher risk for Alzheimer’s disease and help educate them on how to maintain brain health, both through Dr. Carlsson’s research and clinical practice and Mr. King’s outreach to veterans and Native Americans. Discussing the importance of current outreach and educational efforts as well as what they’ve learned from engaging with veterans and Native Americans, Dr. Carlsson and Mr. King describes how understanding different cultures and community experiences can help Alzheimer’s disease research better support underserved populations. Guests: Cynthia Carlsson, MD, MS, professor of medicine and Alzheimer’s disease researcher, University of Wisconsin School of Medicine and Public Health, geriatrician, William S. Middleton Memorial Veterans Hospital, and

Research in the field of fluid biomarkers is leading to new developments in Alzheimer’s disease identification, including new tests that can predict Alzheimer’s based on biomarkers in blood. Ahead of his keynote address as part of Alzheimer's Disease & Related Dementias Research Day on April 5, 2022, Dr. Thomas Karikari joins the podcast to discuss his work with these new blood tests, how accurate they are, and what research needs to be done before they are made available for clinical use. Guest: Thomas Karikari, PhD, assistant professor, University of Gothenburg, University of Pittsburgh Episode Topics 3:12 How close do you think we are to using these Alzheimer’s tests in doctor’s offices? 8:28 How accurate are the current available tests, such as spinal taps and these new blood tests, at identifying Alzheimer’s disease? 17:40 How early can these tests identify Alzheimer’s disease proteins before an individual shows symptoms? 21:41 How accurate can the risk calculators used with the blood tests be?

The Puglielli lab at the University of Wisconsin School of Medicine and Public Health has found a way to manipulate autophagy — a process where cells clean out damaged materials — to rid the brain of toxic proteins like amyloid and tau. Researchers hope to use the power of this process to develop future treatments for Alzheimer’s disease and other diseases of aging. Luigi Puglielli joins the podcast to discuss his team’s research over the past 15 years, why the scientific process can take years to turn ideas into possible treatments, and how he hopes this research can be used in the future. Guest: Luigi Puglielli, MD, PhD, professor of medicine, University of Wisconsin School of Medicine and Public Health Episode Topics 7:47 Tell us about how you manipulated this process of autophagy. Why is this discovery so important? 15:14 What role does acetyl-CoA play in the brain? 19:58 What does the future look like for this research? Show Notes Learn more about Luigi Puglielli, MD, PhD, and his work in his bio an

A recent study from Alzheimer’s disease researchers at the University of Wisconsin–Madison used neuroimaging technology called 4D Flow MRI to study the relationship between blood vessel disease and Alzheimer’s disease. Published in December 2021, the study found that people with Alzheimer’s disease symptoms had stiffer blood vessels in their brains, which could lead to inflammation and a buildup of Alzheimer’s biomarkers like amyloid and tau proteins. Lead researcher Leonardo Rivera-Rivera joins the podcast to discuss his findings, the developments made with new 4D Flow MRI scans, and how these developments could impact future Alzheimer’s disease research and clinical practices. Guest: Leonardo Rivera-Rivera, PhD, neuroimaging scientist, Wisconsin Alzheimer’s Disease Research Center Episode Topics 8:55 How does the 4D Flow MRI technology used in your study compare to MRIs used in clinics? 13:18 What did you look at in your study? What were your findings? 17:54 Did you see more pronounced findings in parti

On January 11, the Centers for Medicare and Medicaid Services (CMS) announced its much-anticipated coverage proposal for monoclonal antibody treatments that target amyloid for the treatment of Alzheimer’s disease. According to the proposed policy, this class of drugs, which includes aducanumab, also known by the brand name Aduhelm, would be covered for people with Medicare only if they are enrolled in qualifying clinical trials. Dr. Jason Karlawish joins the podcast to discuss the recent proposal, share his reaction to the decision, and tell us how this coverage policy could impact the development of other Alzheimer’s disease treatments in the future. Guest: Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania Episode Topics 1:48 What’s the difference between the FDA and Centers for Medicare and Medicaid Services? 3:58 What is the purpose of sharing a proposal and allowing public comment after? Is it possibl

In November 2021, Brigham and Women’s Hospital in Boston launched the first human trial of a nasal vaccine for Alzheimer’s disease. Nearly 20 years of research went into developing the vaccine, which uses the immune system to clear Alzheimer’s disease-related proteins from the brain. Lead researcher Dr. Howard Weiner joins the podcast to discuss the science behind the vaccine and how it could introduce new ways of treating other neurodegenerative diseases in the future. Guest: Howard Weiner, MD, professor of neurology, Harvard Medical School, co-director, Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital Episode Topics How does the vaccine work? Why would a vaccine be a potentially better approach to treatment than a monoclonal antibody? Do you think a vaccine could ever be used for prevention reasons instead of treatment? Why a nasal vaccine versus into the muscle, like the COVID vaccine or flu vaccine? Show Notes Learn more about Brigham and Women’s Hospital’s nasal vaccine trial

Medical anthropologist and professor of humanities and public health sciences Daniel George, PhD, and professor of neurology and medicine Peter Whitehouse, MD, PhD, join the podcast to discuss their recent book, American Dementia: Brain Health in an Unhealthy Society. In it, they argue that 20th century policies focused on reducing inequality, increasing access to education and healthcare, and protecting the environment contributed to today’s declining dementia rates, but inequalities in the 21st century are reversing these trends. Discussing the pros and cons of current social and clinical approaches to Alzheimer’s disease, our guests challenge assumptions about dementia caregiving and show how we can work together to create a healthier society. Guests: Daniel George, PhD, medical anthropologist, associate professor of humanities and public health sciences, Penn State College of Medicine, and Peter Whitehouse, MD, PhD, professor of neurology, Case Western University, professor of medicine, University of Tor

There are many common beliefs about metabolism. Perhaps you’ve heard that a person’s metabolism slows around middle age, or that a woman’s metabolism is slower than a man’s. However widespread these beliefs are, recent research from the journal Science has found that these conceptions of metabolism are wrong. In a groundbreaking study, researchers have found that metabolism goes through four key phases over our lives, only beginning to slow around age 60. This, among other findings, are now changing how we think about human physiology and how we think about aging. Breaking down this new research and his perspective article on the findings, Dr. Rhoads describes our shifting understandings of metabolism and how it impacts chronic diseases like Alzheimer’s disease as we age. Guest: Tim Rhoads, PhD, assistant scientist, Rozalyn Anderson laboratory, University of Wisconsin School of Medicine and Public Health Episode Topics 2:30 - How is metabolism related to diseases of aging? 4:42 - What are the four distinct

Dementia impacts a person’s ability to complete day-to-day activities like familiar tasks at work or at home. What if we could identify these changes in everyday behaviors early enough to identify preclinical Alzheimer’s disease? That’s what Dr. Sayeh Bayat, an assistant professor at the University of Calgary, looked to find out. Dr. Bayat is the lead author of a recent paper highlighting how driving behaviors such as braking, following the speed limit and the number of trips taken could predict preclinical Alzheimer’s disease. Dr. Bayat joined the podcast to share findings from the paper and discuss some of the ways engineering and machine learning can help us discover more about dementia and aging. Guest: Sayeh Bayat, PhD, assistant professor, Department of Geomatics Engineering, University of Calgary Episode Topics 1:05 - What led you to study this intersection of engineering and aging? 3:23 - What inspired you to study the topic of driving and aging? 5:30 - Who was involved in the study, and how long

Alzheimer’s Disease International’s World Alzheimer’s Report 2021 recently found that 75% of people with dementia are undiagnosed, equating to 41 million people across the globe. The report, subtitled “Journey through the diagnosis of dementia,” also found clinician stigma is still a major barrier to diagnosis, and one in three believe nothing can be done about dementia. Dr. Serge Gauthier, co-author of the report, joins the podcast to discuss these findings, recommendations for improving dementia diagnoses, and more from the report. Episode Topics 2:00 - How did you get into this field, and why did you choose to study dementia?  3:04 - What was the methodology behind this research? What was that process like to collect this data? 5:47 - What are some of the key findings that you took away from the report? 7:59 - What did you discover about stigma while conducting this report? Why is that important to this discussion about diagnosis and subsequent care? 9:47 - How can people encourage their healthcare sy